vTv Therapeutics says FDA grants orphan drug designation to HPPD in sickle cell disease
VTVT•The FDA granted orphan drug designation to vTv Therapeutics’ HPPD for sickle cell disease; the oral Nrf2/Bach1 modulator is in preclinical development.
1. FDA designation
The FDA granted orphan drug designation to vTv Therapeutics’ HPPD for sickle cell disease. HPPD is an oral Nrf2/Bach1 modulator in preclinical development.
